

Retraction: Zerumbone Abolishes RANKL-Induced NF- κ B Activation, Inhibits Osteoclastogenesis, and Suppresses Human Breast Cancer-Induced Bone Loss in Athymic Nude Mice



This article (1) has been retracted at the request of the editors. Following an institutional review, it was determined that the same image was used to represent zerumbone (day 0) and zerumbone (after day 3) in Fig. 4A. In addition, a second image from a previously published article (2) was used to represent zerumbone (after day 1) in Fig. 4A. The original research records related to the figures were not available during the review. Therefore, the institution was not able to determine which of the published images were correct.

A copy of this Retraction Notice was sent to the last known e-mail addresses for all four authors. One author (B.O. Oyajobi) agreed to the retraction; two authors (B. Sung and B.B. Aggarwal) did not agree to the retraction; the remaining author (A. Murakami) did not respond.

References

1. Sung B, Murakami A, Oyajobi BO, Aggarwal BB. Zerumbone abolishes RANKL-induced NF- κ B activation, inhibits osteoclastogenesis, and suppresses human breast cancer-induced bone loss in athymic nude mice. *Cancer Res* 2009;69:1477–84.
2. Ichikawa H, Aggarwal BB. Guggulsterone inhibits osteoclastogenesis induced by receptor activator of nuclear factor- κ B ligand and by tumor cells by suppressing nuclear factor- κ B activation. *Clin Cancer Res* 2006;12:662–8.

Published online September 4, 2018.
doi: 10.1158/0008-5472.CAN-18-1827
©2018 American Association for Cancer Research.

Cancer Research

The Journal of Cancer Research (1916–1930) | The American Journal of Cancer (1931–1940)

Retraction: Zerumbone Abolishes RANKL-Induced NF- κ B Activation, Inhibits Osteoclastogenesis, and Suppresses Human Breast Cancer–Induced Bone Loss in Athymic Nude Mice

Cancer Res 2018;78:5186.

Updated version Access the most recent version of this article at:
<http://cancerres.aacrjournals.org/content/78/17/5186>

Cited articles This article cites 2 articles, 2 of which you can access for free at:
<http://cancerres.aacrjournals.org/content/78/17/5186.full#ref-list-1>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link
<http://cancerres.aacrjournals.org/content/78/17/5186>.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.